25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

PER (Percheron Therapeutics Limited) Stock Analysis
Buy, Hold or Sell?

Let's analyze Percheron Therapeutics Limited together

I guess you are interested in Percheron Therapeutics Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Percheron Therapeutics Limited’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Percheron Therapeutics Limited’s Price Targets

I'm going to help you getting a better view of Percheron Therapeutics Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Percheron Therapeutics Limited

I send you an email if I find something interesting about Percheron Therapeutics Limited.

1. Quick Overview

1.1. Quick analysis of Percheron Therapeutics Limited (30 sec.)










1.2. What can you expect buying and holding a share of Percheron Therapeutics Limited? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$0.01
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$0.00
Return On Investment
-20.5%

For what price can you sell your share?

Current Price per Share
A$0.01
Expected price per share
A$0.009 - A$0.011
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Percheron Therapeutics Limited (5 min.)




Live pricePrice per Share (EOD)
A$0.01
Intrinsic Value Per Share
A$-0.13 - A$-0.06
Total Value Per Share
A$-0.12 - A$-0.05

2.2. Growth of Percheron Therapeutics Limited (5 min.)




Is Percheron Therapeutics Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$5.8m$6.2m-$385.9k-6.5%

How much money is Percheron Therapeutics Limited making?

Current yearPrevious yearGrowGrow %
Making money-$7.5m-$7.1m-$339.8k-4.5%
Net Profit Margin0.0%-2,956.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Percheron Therapeutics Limited (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Percheron Therapeutics Limited?

Welcome investor! Percheron Therapeutics Limited's management wants to use your money to grow the business. In return you get a share of Percheron Therapeutics Limited.

First you should know what it really means to hold a share of Percheron Therapeutics Limited. And how you can make/lose money.

Speculation

The Price per Share of Percheron Therapeutics Limited is A$0.011. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Percheron Therapeutics Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Percheron Therapeutics Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Percheron Therapeutics Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-62.8%-0.01-62.8%-0.01-59.9%0.00-45.4%0.00-27.9%
Usd Book Value Change Per Share0.00-3.2%0.00-3.2%-0.01-58.8%0.006.9%0.003.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.3%0.000.1%
Usd Total Gains Per Share0.00-3.2%0.00-3.2%-0.01-58.8%0.007.2%0.004.0%
Usd Price Per Share0.05-0.05-0.04-0.06-0.05-
Price to Earnings Ratio-7.75--7.75--5.64--13.47-5.78-
Price-to-Total Gains Ratio-150.89--150.89--5.75-11.73-3.38-
Price to Book Ratio9.87-9.87-6.43-14.99-14.41-
Price-to-Total Gains Ratio-150.89--150.89--5.75-11.73-3.38-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.00693
Number of shares144300
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (144300 shares)-51.21113.91
Gains per Year (144300 shares)-204.84455.66
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-205-21517438446
20-410-42035877902
30-615-6255213151358
40-819-8306917531814
50-1024-10358721912270
60-1229-124010426302726
70-1434-144512230683182
80-1639-165013935063638
90-1844-185515639454094
100-2048-206017443834550

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%1.09.00.010.0%1.023.00.04.2%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%5.05.00.050.0%10.014.00.041.7%
Dividend per Share0.00.01.00.0%1.00.02.033.3%3.00.02.060.0%3.00.07.030.0%3.00.021.012.5%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%5.05.00.050.0%10.014.00.041.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Percheron Therapeutics Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.001-0.0010%-0.010+1723%0.001-147%0.001-184%
Book Value Per Share--0.0090.0090%0.009-6%0.009-8%0.007+31%
Current Ratio--2.8092.8090%4.513-38%7.880-64%7.582-63%
Debt To Asset Ratio--0.3560.3560%0.223+59%0.194+83%0.182+95%
Debt To Equity Ratio--0.5520.5520%0.287+92%0.261+112%0.237+132%
Dividend Per Share----0%-0%0.000-100%0.000-100%
Enterprise Value--87265193.00087265193.0000%72258856.000+21%111905383.800-22%85146218.000+2%
Eps---0.011-0.0110%-0.010-5%-0.008-28%-0.005-56%
Ev To Ebitda Ratio--infinfnan%-5.454nan%infnan%infnan%
Ev To Sales Ratio--infinfnan%187.724+inf%infnan%infnan%
Free Cash Flow Per Share---0.009-0.0090%-0.008-19%-0.007-29%-0.004-59%
Free Cash Flow To Equity Per Share--0.0010.0010%-0.008+1019%0.002-50%0.001-33%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.062--------
Intrinsic Value_10Y_min---0.128--------
Intrinsic Value_1Y_max---0.004--------
Intrinsic Value_1Y_min---0.009--------
Intrinsic Value_3Y_max---0.015--------
Intrinsic Value_3Y_min---0.031--------
Intrinsic Value_5Y_max---0.026--------
Intrinsic Value_5Y_min---0.056--------
Market Cap11961840.000-673%92432400.00092432400.0000%64158960.000+44%106134144.000-13%80535806.400+15%
Net Profit Margin----0%-29.5640%-464.6270%-249.1400%
Operating Margin----0%-34.6690%-510.6080%-275.9380%
Operating Ratio----0%34.669-100%510.608-100%277.599-100%
Pb Ratio1.278-673%9.8729.8720%6.432+53%14.989-34%14.407-31%
Pe Ratio-1.004+87%-7.755-7.7550%-5.638-27%-13.471+74%5.784-234%
Price Per Share0.011-673%0.0850.0850%0.059+44%0.098-13%0.074+15%
Price To Free Cash Flow Ratio-1.182+87%-9.134-9.1340%-7.843-14%-16.812+84%-479.333+5148%
Price To Total Gains Ratio-19.527+87%-150.891-150.8910%-5.746-96%11.733-1386%3.385-4558%
Quick Ratio--0.0160.0160%8.223-100%10.908-100%9.402-100%
Return On Assets---0.820-0.8200%-0.886+8%-0.844+3%-0.679-17%
Return On Equity---1.273-1.2730%-1.141-10%-1.080-15%-0.871-32%
Total Gains Per Share---0.001-0.0010%-0.010+1723%0.001-145%0.001-181%
Usd Book Value--5898744.8105898744.8100%6284668.950-6%6393077.838-8%4491386.613+31%
Usd Book Value Change Per Share--0.0000.0000%-0.006+1723%0.001-147%0.000-184%
Usd Book Value Per Share--0.0050.0050%0.006-6%0.006-8%0.004+31%
Usd Dividend Per Share----0%-0%0.000-100%0.000-100%
Usd Enterprise Value--54977071.59054977071.5900%45523079.280+21%70500391.794-22%53642117.340+2%
Usd Eps---0.007-0.0070%-0.007-5%-0.005-28%-0.003-56%
Usd Free Cash Flow---6375259.170-6375259.1700%-5153790.600-19%-4524317.658-29%-2640276.261-59%
Usd Free Cash Flow Per Share---0.006-0.0060%-0.005-19%-0.004-29%-0.002-59%
Usd Free Cash Flow To Equity Per Share--0.0010.0010%-0.005+1019%0.001-50%0.001-33%
Usd Market Cap7535959.200-673%58232412.00058232412.0000%40420144.800+44%66864510.720-13%50737558.032+15%
Usd Price Per Share0.007-673%0.0540.0540%0.037+44%0.061-13%0.047+15%
Usd Profit---7509110.490-7509110.4900%-7169291.640-5%-5429407.158-28%-3294253.242-56%
Usd Revenue----0%242499.600-100%57180.060-100%345153.879-100%
Usd Total Gains Per Share--0.0000.0000%-0.006+1723%0.001-145%0.000-181%
 EOD+3 -5MRQTTM+0 -0YOY+16 -185Y+4 -3110Y+11 -24

3.3 Fundamental Score

Let's check the fundamental score of Percheron Therapeutics Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.004
Price to Book Ratio (EOD)Between0-11.278
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.016
Current Ratio (MRQ)Greater than12.809
Debt to Asset Ratio (MRQ)Less than10.356
Debt to Equity Ratio (MRQ)Less than10.552
Return on Equity (MRQ)Greater than0.15-1.273
Return on Assets (MRQ)Greater than0.05-0.820
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Percheron Therapeutics Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.625
Ma 20Greater thanMa 500.011
Ma 50Greater thanMa 1000.010
Ma 100Greater thanMa 2000.030
OpenGreater thanClose0.011
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Percheron Therapeutics Limited

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2025-03-09 17:56:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Percheron Therapeutics Limited earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Percheron Therapeutics Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Percheron Therapeutics Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-2,956.4%+2,956.4%
TTM-5Y-46,462.7%+46,462.7%
5Y-46,462.7%10Y-24,914.0%-21,548.6%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Percheron Therapeutics Limited is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Percheron Therapeutics Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • -82.0% Return on Assets means thatΒ Percheron Therapeutics Limited generatedΒ $-0.82 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Percheron Therapeutics Limited:

  • The MRQ is -82.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -82.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-82.0%TTM-82.0%0.0%
TTM-82.0%YOY-88.6%+6.6%
TTM-82.0%5Y-84.4%+2.4%
5Y-84.4%10Y-67.9%-16.5%
4.3.1.3. Return on Equity

Shows how efficient Percheron Therapeutics Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Percheron Therapeutics Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • -127.3% Return on Equity means Percheron Therapeutics Limited generated $-1.27Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Percheron Therapeutics Limited:

  • The MRQ is -127.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -127.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-127.3%TTM-127.3%0.0%
TTM-127.3%YOY-114.1%-13.2%
TTM-127.3%5Y-108.0%-19.3%
5Y-108.0%10Y-87.1%-20.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Percheron Therapeutics Limited.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Percheron Therapeutics Limited is operatingΒ .

  • Measures how much profit Percheron Therapeutics Limited makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Percheron Therapeutics Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Percheron Therapeutics Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-3,466.9%+3,466.9%
TTM-5Y-51,060.8%+51,060.8%
5Y-51,060.8%10Y-27,593.8%-23,467.1%
4.3.2.2. Operating Ratio

Measures how efficient Percheron Therapeutics Limited is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY34.669-34.669
TTM-5Y510.608-510.608
5Y510.60810Y277.599+233.009
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Percheron Therapeutics Limited.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Percheron Therapeutics Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.81Β means the company has $2.81 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 2.809. The company is able to pay all its short-term debts. +1
  • The TTM is 2.809. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.809TTM2.8090.000
TTM2.809YOY4.513-1.704
TTM2.8095Y7.880-5.071
5Y7.88010Y7.582+0.298
4.4.3.2. Quick Ratio

Measures if Percheron Therapeutics Limited is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Percheron Therapeutics Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.02Β means the company can pay off $0.02 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 0.016. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.016. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.016TTM0.0160.000
TTM0.016YOY8.223-8.207
TTM0.0165Y10.908-10.892
5Y10.90810Y9.402+1.506
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Percheron Therapeutics Limited.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Percheron Therapeutics LimitedΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Percheron Therapeutics Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.36Β means that Percheron Therapeutics Limited assets areΒ financed with 35.6% credit (debt) and the remaining percentage (100% - 35.6%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 0.356. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.356. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.356TTM0.3560.000
TTM0.356YOY0.223+0.132
TTM0.3565Y0.194+0.161
5Y0.19410Y0.182+0.012
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Percheron Therapeutics Limited is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Percheron Therapeutics Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 55.2% means that company has $0.55 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 0.552. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.552. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.552TTM0.5520.000
TTM0.552YOY0.287+0.264
TTM0.5525Y0.261+0.291
5Y0.26110Y0.237+0.023
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Percheron Therapeutics Limited generates.

  • Above 15 is considered overpriced butΒ always compareΒ Percheron Therapeutics Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -7.75 means the investor is paying $-7.75Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Percheron Therapeutics Limited:

  • The EOD is -1.004. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.755. Based on the earnings, the company is expensive. -2
  • The TTM is -7.755. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.004MRQ-7.755+6.751
MRQ-7.755TTM-7.7550.000
TTM-7.755YOY-5.638-2.117
TTM-7.7555Y-13.471+5.716
5Y-13.47110Y5.784-19.254
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Percheron Therapeutics Limited:

  • The EOD is -1.182. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.134. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.134. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.182MRQ-9.134+7.952
MRQ-9.134TTM-9.1340.000
TTM-9.134YOY-7.843-1.291
TTM-9.1345Y-16.812+7.678
5Y-16.81210Y-479.333+462.521
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Percheron Therapeutics Limited is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 9.87 means the investor is paying $9.87Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Percheron Therapeutics Limited:

  • The EOD is 1.278. Based on the equity, the company is underpriced. +1
  • The MRQ is 9.872. Based on the equity, the company is overpriced. -1
  • The TTM is 9.872. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD1.278MRQ9.872-8.594
MRQ9.872TTM9.8720.000
TTM9.872YOY6.432+3.440
TTM9.8725Y14.989-5.117
5Y14.98910Y14.407+0.582
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Percheron Therapeutics Limited.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets14,530
Total Liabilities5,167
Total Stockholder Equity9,363
 As reported
Total Liabilities 5,167
Total Stockholder Equity+ 9,363
Total Assets = 14,530

Assets

Total Assets14,530
Total Current Assets14,473
Long-term Assets57
Total Current Assets
Cash And Cash Equivalents 11,867
Net Receivables 84
Total Current Assets  (as reported)14,473
Total Current Assets  (calculated)11,951
+/- 2,522
Long-term Assets
Property Plant Equipment 57
Long-term Assets  (as reported)57
Long-term Assets  (calculated)57
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,152
Long-term Liabilities15
Total Stockholder Equity9,363
Total Current Liabilities
Accounts payable 3,729
Total Current Liabilities  (as reported)5,152
Total Current Liabilities  (calculated)3,729
+/- 1,423
Long-term Liabilities
Long-term Liabilities  (as reported)15
Long-term Liabilities  (calculated)0
+/- 15
Total Stockholder Equity
Total Stockholder Equity (as reported)9,363
Total Stockholder Equity (calculated)0
+/- 9,363
Other
Capital Stock109,371
Common Stock Shares Outstanding 901,545
Net Invested Capital 9,363
Net Working Capital 9,321
Property Plant and Equipment Gross 311



5.2. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-30
> Total Assets 
20,088
15,334
11,982
18,151
11,222
9,116
8,050
9,866
4,989
1,816
2,436
5,689
5,201
2,656
7,673
5,327
2,539
4,802
3,699
5,352
7,001
22,437
12,843
14,530
14,53012,84322,4377,0015,3523,6994,8022,5395,3277,6732,6565,2015,6892,4361,8164,9899,8668,0509,11611,22218,15111,98215,33420,088
   > Total Current Assets 
13,686
9,566
7,493
14,943
9,301
8,649
8,032
9,852
4,981
1,801
2,428
5,674
5,188
2,642
7,668
5,324
2,525
4,794
3,696
5,214
6,699
22,220
12,692
14,473
14,47312,69222,2206,6995,2143,6964,7942,5255,3247,6682,6425,1885,6742,4281,8014,9819,8528,0328,6499,30114,9437,4939,56613,686
       Cash And Cash Equivalents 
13,675
9,373
6,546
14,421
8,821
8,239
7,597
6,362
3,076
1,726
2,338
4,968
4,000
1,335
6,830
4,801
1,902
1,899
2,904
4,059
6,020
19,233
10,967
11,867
11,86710,96719,2336,0204,0592,9041,8991,9024,8016,8301,3354,0004,9682,3381,7263,0766,3627,5978,2398,82114,4216,5469,37313,675
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,400
0
0
0
18,416
10,500
0
010,50018,4160002,40000000000000000000
       Net Receivables 
11
53
69
222
77
92
369
3,276
1,846
17
27
624
1,013
1,168
744
420
428
331
606
689
601
1,841
1,659
84
841,6591,8416016896063314284207441,1681,01362427171,8463,2763699277222695311
       Other Current Assets 
0
140
879
300
403
318
66
214
60
58
63
82
175
140
94
103
195
164
257
257
665
533
1,467
0
01,4675336652572571641951039414017582635860214663184033008791400
   > Long-term Assets 
6,402
5,768
4,489
3,208
1,921
467
18
14
8
14
8
15
13
14
5
3
14
8
2
138
302
217
151
57
57151217302138281435141315814814184671,9213,2084,4895,7686,402
       Property Plant Equipment 
15
52
51
47
38
21
18
14
8
14
8
15
13
14
5
3
14
8
2
138
302
217
151
57
5715121730213828143514131581481418213847515215
       Intangible Assets 
6,388
5,716
4,438
3,161
1,883
446
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000004461,8833,1614,4385,7166,388
> Total Liabilities 
54
1,853
364
1,018
358
323
2,032
3,531
1,062
471
418
423
554
569
581
750
686
581
889
821
1,273
1,295
2,867
5,167
5,1672,8671,2951,2738218895816867505815695544234184711,0623,5312,0323233581,0183641,85354
   > Total Current Liabilities 
54
1,853
364
1,018
358
323
1,973
3,435
1,019
456
418
423
554
569
581
750
686
581
880
799
1,046
1,161
2,812
5,152
5,1522,8121,1611,0467998805816867505815695544234184561,0193,4351,9733233581,0183641,85354
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
50
0
0
0
2,400
113
113
79
94
94
0
09494791131132,400000500000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
50
0
0
0
0
0
0
0
0
0
0
0000000000500000000000000
       Accounts payable 
0
0
0
95
44
24
26
1,027
601
29
52
14
160
117
175
215
166
104
227
108
157
331
1,023
3,729
3,7291,0233311571082271041662151751171601452296011,02726244495000
       Other Current Liabilities 
54
50
38
924
110
299
1,947
2,409
418
427
366
409
394
402
420
535
520
477
653
691
888
829
1,789
0
01,7898298886916534775205354204023944093664274182,4091,947299110924385054
   > Long-term Liabilities 
0
0
0
0
0
0
59
95
43
15
0
0
0
0
0
0
0
0
9
23
228
134
55
15
15551342282390000000015439559000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23
227
133
48
0
048133227230000000000000000000
       Other Liabilities 
0
0
0
0
0
0
59
95
43
15
0
0
0
0
0
0
0
0
9
0
0
1
7
0
0710090000000015439559000000
> Total Stockholder Equity
20,034
13,482
11,618
17,133
10,864
8,793
6,017
6,335
3,928
1,344
2,018
5,266
4,647
2,087
7,092
4,577
1,853
4,221
2,810
4,531
5,728
21,141
9,976
9,363
9,3639,97621,1415,7284,5312,8104,2211,8534,5777,0922,0874,6475,2662,0181,3443,9286,3356,0178,79310,86417,13311,61813,48220,034
   Common Stock
20,428
19,471
23,715
33,839
33,837
37,215
39,263
41,434
41,434
42,194
44,674
49,723
51,784
52,417
56,715
56,715
57,707
62,406
63,938
69,148
77,034
98,135
98,263
0
098,26398,13577,03469,14863,93862,40657,70756,71556,71552,41751,78449,72344,67442,19441,43441,43439,26337,21533,83733,83923,71519,47120,428
   Retained Earnings -101,730-92,289-80,909-75,098-67,037-61,129-58,184-55,853-53,098-50,584-51,291-48,278-45,823-44,022-42,208-38,783-36,133-33,996-29,161-23,698-17,432-12,823-6,715-394
   Accumulated Other Comprehensive Income 
-1
-11
726
726
726
739
750
1,034
1,276
1,358
1,366
1,366
1,141
961
961
961
-178
-184
2,420
2,420
3,791
3,916
4,002
0
04,0023,9163,7912,4202,420-184-1789619619611,1411,3661,3661,3581,2761,034750739726726726-11-1
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
1
737
754
775
796
827
766
1,146
1,396
1,485
1,500
1,507
1,290
1,119
1,128
1,134
178
184
-2,420
2,717
3,791
3,916
4,002
0
04,0023,9163,7912,717-2,4201841781,1341,1281,1191,2901,5071,5001,4851,3961,1467668277967757547371



5.3. Balance Sheets

Currency in AUD. All numbers in thousands.




5.4. Cash Flows

Currency in AUD. All numbers in thousands.




5.5. Income Statements

Currency in AUD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-0
Operating Income-14,8800
 
Operating Expense (+$)
Research Development10,699
Selling General Administrative4,039
Selling And Marketing Expenses0
Operating Expense014,739
 
Net Interest Income (+$)
Interest Income615
Interest Expense-4
Other Finance Cost-0
Net Interest Income612
 
Pretax Income (+$)
Operating Income-14,880
Net Interest Income612
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-11,919-17,229
EBIT - interestExpense = -4
-11,919
-11,916
Interest Expense4
Earnings Before Interest and Taxes (EBIT)0-11,916
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-11,919
Tax Provision-0
Net Income From Continuing Ops-11,919-11,919
Net Income-11,919
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net2,349-612
 

Technical Analysis of Percheron Therapeutics Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Percheron Therapeutics Limited. The general trend of Percheron Therapeutics Limited is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Percheron Therapeutics Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Percheron Therapeutics Limited Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Percheron Therapeutics Limited.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.011 < 0.011 < 0.011.

The bearish price targets are: 0.01 > 0.009 > 0.009.

Know someone who trades $PER? Share this with them.πŸ‘‡

Percheron Therapeutics Limited Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Percheron Therapeutics Limited. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Percheron Therapeutics Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Percheron Therapeutics Limited. The current macd is -0.00015611.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Percheron Therapeutics Limited price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Percheron Therapeutics Limited. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Percheron Therapeutics Limited price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Percheron Therapeutics Limited Daily Moving Average Convergence/Divergence (MACD) ChartPercheron Therapeutics Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Percheron Therapeutics Limited. The current adx is 15.98.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Percheron Therapeutics Limited shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Percheron Therapeutics Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Percheron Therapeutics Limited. The current sar is 0.01317081.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Percheron Therapeutics Limited Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Percheron Therapeutics Limited. The current rsi is 50.62. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
Percheron Therapeutics Limited Daily Relative Strength Index (RSI) ChartPercheron Therapeutics Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Percheron Therapeutics Limited. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Percheron Therapeutics Limited price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Percheron Therapeutics Limited Daily Stochastic Oscillator ChartPercheron Therapeutics Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Percheron Therapeutics Limited. The current cci is 27.21.

Percheron Therapeutics Limited Daily Commodity Channel Index (CCI) ChartPercheron Therapeutics Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Percheron Therapeutics Limited. The current cmo is 6.04606001.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Percheron Therapeutics Limited Daily Chande Momentum Oscillator (CMO) ChartPercheron Therapeutics Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Percheron Therapeutics Limited. The current willr is -33.33333333.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Percheron Therapeutics Limited is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Percheron Therapeutics Limited Daily Williams %R ChartPercheron Therapeutics Limited Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Percheron Therapeutics Limited.

Percheron Therapeutics Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Percheron Therapeutics Limited. The current atr is 0.00132582.

Percheron Therapeutics Limited Daily Average True Range (ATR) ChartPercheron Therapeutics Limited Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Percheron Therapeutics Limited. The current obv is -348,911,145.

Percheron Therapeutics Limited Daily On-Balance Volume (OBV) ChartPercheron Therapeutics Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Percheron Therapeutics Limited. The current mfi is 45.09.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Percheron Therapeutics Limited Daily Money Flow Index (MFI) ChartPercheron Therapeutics Limited Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Percheron Therapeutics Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-31STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-01-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-21MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Percheron Therapeutics Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Percheron Therapeutics Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.625
Ma 20Greater thanMa 500.011
Ma 50Greater thanMa 1000.010
Ma 100Greater thanMa 2000.030
OpenGreater thanClose0.011
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Percheron Therapeutics Limited with someone you think should read this too:
  • Are you bullish or bearish on Percheron Therapeutics Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Percheron Therapeutics Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Percheron Therapeutics Limited

I send you an email if I find something interesting about Percheron Therapeutics Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Percheron Therapeutics Limited.

Receive notifications about Percheron Therapeutics Limited in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.